Table 1.

Overview of treatment characterisitics, PSA response ≥ 50% and overall survival of ¹⁷⁷Lu-PSMA RLT in published retrospective and prospective trails.

Reference	n	Dose per Cycle(GBq)	Median No of Cycles	Interval between Cycles (Weeks)	PSA Decline ≥ 50%(%)	Overall Survival (Months)
Retrospective trials
Rahbar et al. [24]	145	2.0–8.0	2	8–12	45	Not reported
Rasul et al. [32]	54	7.3	3	4	54	28
Ahmadzadehfar et al. [34]	22	4.1–7.1	2	Not reported	60	Not reported
Ahmadzadehfar et al. [35]	52	4.0–7.2	1	/	44	13.8
Ahmadzadehfar et al. [36]	393	6.9	1	/	42	11.1
Braeuer et al. [37]	59	6.1	3	8	53	8
Kessel et al. [38]	109	6.2	3	6–8	25	9.9
Heck et al. [39]	100	7.4	2	6–8	38	12.9
Rahbar et al. [40]	28	6.0	2	8	32	6.8
Rahbar et al. [41]	104	6.1	3	8	33	14
Khreish et al. [42]	28	6.5	4	6	57	12
von Eyben et al. 1 [43]	45	4.6	3	8	80	42
Barber et al. [44]	167	6.3	3	6	48	18
Ahmadzadehfar et al. [45]	100	6.0	3	8	38	15
Rathke et al. [46]	100	Not reported	2	8	35	Nor reported
Ferdinandus et al. [47]	40	6.1	1	/	32.5	Not reported
Prospective trails
Hofman et al. [21]	30	4.4–8.7	1–4	6	57	13.5
Violet et al. [48]	50	4.0–8.5	4	6	64	13.3
Hofman et al. [29]	98	6.0–8.5	5	6	66	Not reported
-Vs. Cabazitaxel	85	/	/	/	37	Not reported
Sartor et al. [31]	551	7.4	6	6	46	15.3
-Vs. Standard of care	280		/	/		11.3

¹ only patients with lymphnode metastases were included.